#USA #Biopharmaceutical #Bradenton #Continuity Biosciences #Vicky Papoutsis

Leadership Changes at Continuity Biosciences

Continuity Biosciences, a clinical-stage biotechnology company, has announced the strategic appointment of Vicky Papoutsis to its board of directors. Papoutsis, who brings with her over 25 years of extensive experience in business development and corporate strategy, will play a crucial role as the company amplifies its focus on clinical programs and collaborations.

As Continuity Biosciences transitions from platform development to clinical execution, this pivotal moment in the company’s journey invites experienced leadership. With its flagship pancreatic cancer program now in clinical trials and additional programs making significant progress, the company is intensifying its efforts to forge strategic partnerships. Papoutsis's background in structuring licensing deals and corporate development makes her a perfect fit for the board, given the increasing demand for strategic alliances at Continuity.

Currently serving as the Executive Vice President and Chief Strategy Officer at TerSera Therapeutics, Papoutsis has a well-documented track record of initiating licensing initiatives, mergers and acquisitions, and corporate strategy within the biopharmaceutical landscape. Throughout her impressive career, she has successfully negotiated over 30 strategic operations and has been instrumental in launching three venture-backed life sciences startups.

Robert Whitehead, Co-founder and Executive Chairman of Continuity Biosciences, expressed great enthusiasm about Papoutsis's addition to the board, stating, "I have had the privilege of collaborating with Vicky on various deals over the years and have always appreciated her professionalism, strategic acumen, and remarkable ability to create value through partnerships. As we advance with our clinical and preclinical programs and enhance our strategic collaboration efforts, Vicky's insight will be invaluable. We are delighted to welcome her to our team."

Papoutsis herself remarked on the significance of her new role, saying, "It is an honor to join the board of Continuity Biosciences at such a critical point in the company’s development. Continuity has assembled an exceptional leadership team, scientific advisors, and a board of directors, all while cultivating an innovative portfolio of precise drug delivery technologies across multiple therapeutic areas. I look forward to supporting the company’s long-term strategy, enhancing its strategic partnerships, and contributing to its mission of improving patient outcomes."

Papoutsis’s appointment adds a wealth of business development and transaction expertise to a board that has been thoughtfully constructed to provide specialized knowledge in biotechnology innovation, drug development, healthcare delivery, corporate governance, finance, and strategic business development.

"Together, our board members have founded biotechnology companies, developed and marketed innovative drugs, led globally recognized healthcare organizations, created iconic consumer brands, advised leading life sciences companies, managed investments totaling billions of dollars, and executed transformative strategic transactions," Whitehead added. This aggregated experience positions Continuity Biosciences advantageously to pursue its mission of revolutionizing drug delivery.

Continuity is advancing a portfolio of precise drug delivery platforms designed for localized, sustained, and precisely controlled therapeutic administration. Its technologies include intratumoral drug delivery for solid tumors, nanofluidic implants for sustained local release, subcutaneous long-acting implants, implantable devices for cell therapy, and microneedle systems for precise transdermal delivery. The company's product portfolio spans oncology, type 1 diabetes, endocrinology, HIV prevention, and medical aesthetics, underpinned by collaborations with leading academic institutions, scientific advisors, and strategic partners.

About Continuity Biosciences

Continuity Biosciences is a clinical-stage biotechnology firm dedicated to developing precision drug delivery platforms for local, sustained, and accurately controlled therapeutic administration. The company's programs target oncology, type 1 diabetes, endocrinology, HIV prevention, and medical aesthetics. For more information, please visit continuitybiosciences.com.

About the Board of Directors

• - Michael Fowler: CEO of Affordable Housing Partners, Inc., with expertise in tax-advantaged investments and affordable housing financing.
• - Vicky Papoutsis: Executive VP and Chief Strategy Officer of TerSera Therapeutics, renowned for her leadership in strategic licensing, corporate development, and pharmaceutical alliances.
• - Dr. Monica Reed: President and CEO of UChicago Medicine AdventHealth Great Lakes Region, providing insight into integrated healthcare operations and patient care.
• - Josephine M. Torrente: Former partner at Hyman, Phelps & McNamara, P.C., advising pharmaceutical and medical device companies on regulatory issues and transactions.
• - Ramakrishna (Krishna) Venugopalan, Ph.D.: Co-founder and CEO, with a wealth of experience in pharmaceutical R&D and global product innovation strategy.
• - Allen Weiss: Former President of Global Operations at Walt Disney Parks and Resorts, recognized for operational excellence and customer care.
• - Robert Whitehead: Serial entrepreneur in biotechnology, successfully founding and managing multiple life sciences companies.